Minerval
Sourcejournal articleno stored text

Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients

Stephen J. Nicholls, Adam J. Nelson, Kausik K. Ray, Christie M. Ballantyne, Marc Ditmarsch, Douglas Kling, Andrew Hsieh, Michael Szarek, John J. Kastelein, Michael H. DavidsonJACCPublished Oct 2025doi 10.1016/j.jacc.2025.07.056Original︎ ↗

Claims1
ExaminationsNone
TextNot stored
VersionsOne known
CopiesNone recorded
CorrectionsNone recorded
Facts checked Nov 9, 2026
ReachNo copies recorded
StructureIn 1 claim's map0 sources downstream across 1 claim
EvidenceNot yet read

Examinations

None recorded. An examination is commissioned by a claim’s Steward for what its claim rests on; a review of the document for its own sake is asked for as a request bearing on it.

Text

No stored copy. Only the passages claims quote are recorded.

As quoted

The one CETP inhibitor that was demonstrated to reduce cardiovascular risk, anacetrapib, did not progress

Lineage across 1 claim

Draws on · none recorded
This source
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients
in 1 claim's map
Drawn on by · none recorded

Record

Kind
journal article
Authors
Stephen J. Nicholls, Adam J. Nelson, Kausik K. Ray, Christie M. Ballantyne, Marc Ditmarsch, Douglas Kling, Andrew Hsieh, Michael Szarek, John J. Kastelein, Michael H. Davidson
Publisher
JACC
Published
Oct 2025
DOI
10.1016/j.jacc.2025.07.056
Link
https://www.jacc.org/doi/10.1016/j.jacc.2025.07.056
Archived copy
None found
Stored text
None; quoted passages only
Claims extracted
Not recorded
Versions
One known
Copies
None recorded
Corrections
None recorded
Facts checked
Nov 9, 2026

History 3

  1. Nov 9, 2026FactsFacts fetcher · Facts looked up
  2. Nov 4, 2026Correction watchCorrection watcher · Watched by DOI; no notice found
  3. Aug 9, 2026Entered the graphEntered the graph; no copy stored